Press Release
-
(2023-06-30) AimedBio signs another agreement with GeneQuantum2023.07.18
-
- AimedBio has previously signed an agreement with GeneQuantum to co-develop AMB302/GQ1011 on April 2022.
- Based on good results, AimedBio and GeneQuantum decided to sign another ADC co-development agreement to collaborate on a maximum of five ADCs using AimedBio's antibody development technology and GeneQuantum's linker conjugation technology.
Link to full news: https://firstwordpharma.com/story/5758714
